Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03519412 |
TitlePembrolizumab 在 MMR 精通的转移性结直肠癌中的药理作用触发高突变状态 | 阶段
第二阶段
|
Date Added 2018-05-09 |
地点
意大利
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
pembrolizumab (treatment), temozolomide (induction),, Keytruda, Temodar |
标签
MSS/ MMRp
|
| NCT ID NCT02886585 |
TitlePembrolizumab In Central Nervous System Metastases | 阶段
第二阶段
|
Date Added 2016-09-01 |
地点
Massachusetts, United States
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT04963283 |
TitleStudy of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | 阶段
第二阶段
|
Date Added 2021-07-15 |
地点
Colorado, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Cabozantinib, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT03977090 |
Title庚妥尼单抗（GB226）联合福喹替尼治疗转移性结直肠癌 | 阶段
第 1 阶段
|
Date Added 2019-06-06 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Fruquintinib, Geptanolimab Injection, Elunate |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02298959 |
TitleTesting the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | 阶段
第 1 阶段
|
Date Added 2014-11-24 |
地点
Florida, United States
Maryland, United States Massachusetts, United States 加拿大 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pembrolizumab, Ziv-Aflibercept, Keytruda, Zaltrap |
标签
MSS/ MMRp
|
| NCT ID NCT03844750 |
TitlePembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery | 阶段
第二阶段
|
Date Added 2019-02-18 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pembrolizumab, Vactosertib, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT05243862 |
TitleSafety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | 阶段
第二阶段
|
Date Added 2022-02-17 |
地点
Arizona, United States
Florida, United States Minnesota, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Atezolizumab, PolyPEPI1018, Tecentriq |
标签
MSS/ MMRp
|
| NCT ID NCT04776148 |
TitleStudy of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) | 阶段
第三阶段
|
Date Added 2021-03-01 |
地点
California, United States
Georgia, United States Illinois, United States Maryland, United States Michigan, United States Montana, United States Oregon, United States Pennsylvania, United States Virginia, United States Washington, United States 阿根廷 澳大利亚 加拿大 中国 丹麦 德国 以色列 日本 大韩民国 Russian Federation 西班牙 台湾 Turkey 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Lenvatinib, Pembrolizumab, Regorafenib, TAS-102 (trifluridine and tipiracil) |
标签
MSS/ MMRp
|
| NCT ID NCT04653480 |
TitleSurufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC | 阶段
第二阶段
|
Date Added 2020-12-04 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Chemotherapy, Surufatinib, Toripalimab |
标签
MSS/ MMRp
|
| NCT ID NCT03925662 |
Title甲苯咪唑作为结肠癌的辅助治疗药物 | 阶段
第三阶段
|
Date Added 2019-04-24 |
地点
埃及
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Folfox with avastin, Mebendazole |
标签
MSI-H/ MMRd, MSS/ MMRp
|
